RESUMEN
A simple, precise, accurate, robust chiral high-performance liquid chromatographic (chiral HPLC) method was developed for estimation of (S)-piperidin-3-amine (S-isomer) in (R)-piperidin-3-amine dihydrochloride (R-AMP). As AMP is a high-melting solid and nonchromophoric compound, development of a suitable chiral method is a challenging task. The proposed chiral HPLC-UV method involves a precolumn derivatization technique with para toluene sulphonyl chloride (PTSC) in the presence of a base to introduce chromophore into analytes. It utilizes chiralpak AD-H column with a simple mobile phase of 0.1% diethyl amine in ethanol with a 0.5 mL/min flow rate. Analytes were monitored by using a UV detector at 228 nm. The resolution between the two enantiomers was more than 4.0. The developed method was validated as per current International Conference on Harmonization (ICH) guidelines.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Piperidinas/química , Cromatografía Líquida de Alta Presión/instrumentación , Límite de Detección , Piperidinas/análisis , Reproducibilidad de los Resultados , Soluciones , EstereoisomerismoRESUMEN
A new strategy for converting antipsychotic drug olanzapine into PDE4 inhibitors is described via the design and Pd/C mediated synthesis of novel N-indolylmethyl olanzapine derivatives. One compound showed good inhibition (IC50 1.1 µM) and >10 fold selectivity towards PDE4B over D that was supported by docking studies. This compound also showed significant inhibition of TNF-α and no major toxicities in cell lines and a zebrafish embryo model except the teratogenic effects to be re-assessed in rodents.
Asunto(s)
Antipsicóticos/farmacología , Benzodiazepinas/farmacología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Diseño de Fármacos , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/farmacología , Antipsicóticos/síntesis química , Antipsicóticos/química , Benzodiazepinas/síntesis química , Benzodiazepinas/química , Relación Dosis-Respuesta a Droga , Humanos , Olanzapina , Inhibidores de Fosfodiesterasa 4/química , Relación Estructura-Actividad , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
A series of 1,3-disubstituted pyrrolo[2,3-b]quinoxalines has been designed for the potential inhibition of PDE4 without inhibiting luciferase. A ligand/PTC (phase transfer catalyst) free intramolecular Heck cyclization strategy was used to prepare these compounds, some of which showed significant inhibition of PDE4B (IC50≈ 5-14 µM) and growth inhibition of oral cancer cells (CAL 27) but not inhibition of luciferase in vitro. They also showed acceptable safety profiles but no apoptosis in zebrafish embryos.
Asunto(s)
Neoplasias de la Boca/tratamiento farmacológico , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/farmacología , Quinoxalinas/síntesis química , Quinoxalinas/farmacología , Animales , Sitios de Unión , Catálisis , Proliferación Celular/efectos de los fármacos , Embrión no Mamífero/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Humanos , Ligandos , Luciferasas/metabolismo , Estructura Molecular , Inhibidores de Fosfodiesterasa 4/química , Quinoxalinas/química , Pez Cebra/embriologíaRESUMEN
Deuterium labeled 2,2-dimethyl-[(2)H(6)]-succinic anhydride by a sequence of reactions involving Knoevenagel condensation of [(2)H(6)]-acetone with ethyl cyanoacetate in the presence of piperidine, Michael addition of cyanide, HCl hydrolysis, simultaneous decarboxylation, and subsequent dehydration using acetic anhydride in an overall yield of 34.23% based on [(2)H(6)]-acetone utilized in the reaction is reported. The title compounds were characterized and confirmed spectroscopically by Fourier transform infrared, (1) H-NMR, and Mass. The chemical purity as determined by HPLC was 99%. To the best of our knowledge, the synthesis of these specifically deuterium labeled compounds has not been reported so far.
Asunto(s)
Deuterio/síntesis química , Succinatos/síntesis química , Anhídridos Succínicos/síntesis químicaRESUMEN
In this paper is reported a novel reaction scheme for the no-carrier-added submicromolar scale radiosynthesis of [S-methyl-(14)C]-florfenicol that has been newly designed, developed and employed by us successfully. The [(14)C]-product was obtained in an overall radiochemical yield of 30% based on [(14)C]-methyl iodide taken for the reaction with a radiochemical purity of more than 96%. The specific activity of the product was ~50 mCi (1.85 GBq)/mmol. Chlorosulfonation of compound I was followed by sodium salt formation in situ and it was succeeded by the introduction of [(14)C]-methyl group by coupling with [(14)C]-CH3 I. Subsequently, the oxazolidin-2-one protecting group was opened up by a reaction with sulfuric acid in dioxane and later, the amino group was dichloroacetylated with methyl-2,2-dichloroacetate in triethylamine to obtain [S-methyl-(14)C]-florfenicol.
Asunto(s)
Tianfenicol/análogos & derivados , Radioisótopos de Carbono/química , Técnicas de Química Sintética/métodos , Marcaje Isotópico/métodos , Tianfenicol/síntesis químicaRESUMEN
The design and synthesis of 4-alkynyl pyrazole derivatives has led to the identification of new class of PDE4 inhibitors. All these compounds were accessed for the first time via a facile Pd/C-CuI-PPh(3) mediated C-C bond forming reaction between an appropriate pyrazole iodide and various terminal alkynes. In vitro PDE4B inhibitory properties and molecular modeling studies of some of the compounds synthesized indicated that 4-alkynyl pyrazole could be a promising template for the discovery of novel PDE4 inhibitors.
Asunto(s)
Alquinos/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/química , Inhibidores de Fosfodiesterasa 4/síntesis química , Pirazoles/síntesis química , Alquinos/farmacología , Antidepresivos/síntesis química , Antidepresivos/farmacología , Catálisis , Simulación por Computador , Cobre/química , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Humanos , Yoduros/química , Modelos Moleculares , Paladio/química , Inhibidores de Fosfodiesterasa 4/farmacología , Pirazoles/farmacología , Rolipram/farmacologíaRESUMEN
A regioselective route to novel mono triazolyl substituted quinolines has been developed via copper-catalyzed azide-alkyne cycloaddition (CuAAC) of 2,4-diazidoquinoline with terminal alkynes in DMF. The reaction provided bis triazolyl substituted quinolines when performed in water in the presence of Et(3)N. A number of the compounds synthesized showed promising anti-proliferative properties when tested in vitro especially against breast cancer cells.
Asunto(s)
Alquinos/química , Antineoplásicos/química , Azidas/química , Cobre/química , Quinolinas/química , Solventes/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Ciclización , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Modelos MolecularesRESUMEN
During pregnancy, the disposition of various drugs is altered due to changes in physiological condition, maternal gastrointestinal absorption, gastric secretion and motility. A fixed dose combination of antiretrovirals is commonly prescribed for the treatment of HIV infection. There is a need to understand the pharmacokinetics and placental transfer of efavirenz-emtricitabine-tenofovir in fixed dose combination during pregnancy. The pharmacokinetics and placental transfer of efavirenz-emtricitabine-tenofovir fixed dose combination was evaluated in timed pregnant and non-pregnant Sprague-Dawley rats at 30, 10, 15 mg/kg p.o., respectively. The plasma, placental tissue, amniotic fluid and fetal tissue concentrations were measured using high performance liquid chromatography combined with tandem mass spectrometric detector (LC-MS/MS). To summarize, the pharmacokinetic profile of efavirenz remained similar in the pregnant and non-pregnant rats. However, a considerable difference in the pharmacokinetics of emtricitabine and tenofovir was observed in pregnant and non-pregnant rats. Efavirenz and emtricitabine showed appreciable placental, amniotic fluid and fetal exposure compared with tenofovir. The present study suggests that a profound impact on antiretroviral pharmacokinetics was observed during pregnancy and there is a need to monitor the exposure levels of each drug when administered as a fixed dose combination during pregnancy. Further studies to explore the pharmacokinetic parameters of fixed dose antiretrovirals during the preclinical stage in a timed-pregnancy rat model are required. Such studies can help in the development of safe and effective medications with a reduced risk of perinatal transmission of HIV-1 infection.
Asunto(s)
Adenina/análogos & derivados , Líquido Amniótico/química , Fármacos Anti-VIH/farmacocinética , Desoxicitidina/análogos & derivados , Feto/metabolismo , Intercambio Materno-Fetal , Organofosfonatos/farmacocinética , Oxazinas/farmacocinética , Placenta/metabolismo , Adenina/sangre , Adenina/farmacocinética , Administración Oral , Animales , Fármacos Anti-VIH/sangre , Cromatografía Líquida de Alta Presión , Desoxicitidina/sangre , Desoxicitidina/farmacocinética , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Combinación Efavirenz, Emtricitabina y Fumarato de Tenofovir Disoproxil , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/transmisión , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Intercambio Materno-Fetal/efectos de los fármacos , Organofosfonatos/sangre , Oxazinas/sangre , Embarazo , Ratas Sprague-Dawley , Distribución TisularRESUMEN
A facile two-step method for the construction of fused pyrrole ring leading to 5-substituted 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones via C-C followed by intramolecular C-N bond forming reaction is described. In vitro pharmacological evaluation and molecular modelling studies of some of the compounds synthesized are presented.
Asunto(s)
Compuestos Heterocíclicos con 3 Anillos/síntesis química , Metales Pesados/química , Pirroles/química , Quinolonas/síntesis química , Catálisis , Ciclización , Activación Enzimática/efectos de los fármacos , Compuestos Heterocíclicos con 3 Anillos/farmacología , Humanos , Modelos Moleculares , Estructura Molecular , Sirtuina 1/metabolismoRESUMEN
A sensitive high-performance liquid chromatography-positive ion electrospray tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of methyllycaconitine (MLA) in rat plasma and brain tissue. Following acetonitrile protein precipitation, the analyte was separated using a gradient mobile phase on a reversed-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M + H](+) ions, m/z 683-216 for MLA and m/z 260-116 for the internal standard. The assay exhibited a linear dynamic range of 0.5-250 ng/mL for MLA in rat plasma and brain tissue. The lower limit of quantification was 0.5 ng/mL. Acceptable precision (<12%) and accuracy (100 ± 6%) were obtained for concentrations over the standard curve range. The method was successfully applied to quantify MLA concentrations in a rodent pharmacokinetic and brain penetration study.
Asunto(s)
Aconitina/análogos & derivados , Química Encefálica , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Aconitina/análisis , Aconitina/sangre , Aconitina/farmacocinética , Animales , Encéfalo/metabolismo , Modelos Lineales , Ratas , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
The Pd/C-CuI-PPh(3) catalytic system facilitated C-C bond formation between 4-chlorothieno[2,3-d]pyrimidines and terminal alkynes in methanol with high selectivity without generating any significant side products arising from C-O bond formation between the chloro compounds and methanol. A variety of novel 4-alkynylthieno[2,3- d]pyrimidines were prepared via alkynylation of 4-chlorothieno[2,3-d]pyrimidines in good to excellent yields. Some of the compounds synthesized were tested for cytotoxic activity in vitro.
RESUMEN
An unknown impurity (degradation product) present at a level below 0.1% in the initial sample was increased to 0.25% in 50 degrees C 3 M stability samples of lamivudine, zidovudine and nevirapine tablets for oral suspension, as detected by gradient reverse phase HPLC. This degradation product was isolated using reverse phase preparative HPLC. Based on the spectral data, the structure of this degradation product is characterized as 1-[5-hydroxymethyl-4-(5-methyl-2,3-dihydro-[1,2,3]triazole-1-yl)-tetrahydrofuran-2-yl]-5-methyl-1 H-pyrimidine-2,4-(1H,3H)dione. Structural elucidation of this degradation product was carried out using MS, 1H NMR, 13C NMR, DEPT and IR spectral data. The formation of this impurity and its mechanism are discussed.
Asunto(s)
Fármacos Anti-VIH/análisis , Lamivudine/análisis , Nevirapina/análisis , Zidovudina/análisis , Cromatografía Líquida de Alta Presión , Contaminación de Medicamentos , Indicadores y Reactivos , Espectroscopía de Resonancia Magnética , Espectrometría de Masa por Ionización de Electrospray , Espectrofotometría Ultravioleta , Espectroscopía Infrarroja por Transformada de Fourier , Suspensiones , ComprimidosRESUMEN
BACKGROUND AND THE PURPOSE OF THE STUDY: Lercanidipine hydrochloride (LRDP) is used in the treatment of hypertension because of its selectivity and specificity on the smooth vascular cells. The pharmacokinetic parameters make LRDP a suitable candidate for transdermal delivery. The purpose of the study was to select a suitable formulation for the development of transdermal drug-delivery system (TDDS) of LRDP and to determine the effect of penetration enhancer, limonene on drug permeation METHODS: The matrix type TDDS of LRDP were prepared by solvent evaporation technique. Formulations A1, A2, A3, A4, A5 and A6 were composed of Eudragit RL100 (ERL) and hydroxypropyl methyl cellulose (HPMC) in 1.5:8.5, 3:7, 4:6, 6:4, 7:3 and 8.5:1.5 ratios respectively. All the six formulations carried 10 mg of LRDP/patch area, 8% v/w of d-limonene as a penetration enhancer, 20% v/w of propylene glycol as plasticizer in methanol and dichloromethane as solvent system. The prepared TDDS were evaluated for physicochemical characteristics, in-vitro release, ex-vivo permeation and skin irritation. The ex-vivo permeation studies were carried out across excised rat skin using Franz diffusion cell. RESULTS: All the formulations exhibited satisfactory physicochemical characteristics. Cumulative percentage of the drug released in 24 hrs from the six formulations were 82.0%, 74.9%, 63.2%, 63.5%, 59.8% and 53.5% respectively. Corresponding values for the cumulative amounts of the drug permeated across the rat skin for the above matrix films were 2644.5, 2347.2, 2249.5, 1933.4, 2021.5 and 1663.4 µg/cm(2) respectively. By fitting the data into zero order, first order and Higuchi model, it was concluded that drug release from matrix films followed Higuchi model and the mechanism of the drug release was diffusion mediated. The patches were seemingly free of potentially hazardous skin irritation. CONCLUSIONS: The patches composed of ERL, HPMC (1.5:8.5) with 8% v/w limonene as penetration enhancer may be selected for the development of TDDS of LRDP for potential therapeutic use by using a suitable adhesive layer and backing membrane.
RESUMEN
A high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry method for the simultaneous quantification of efavirenz, emtricitabine and tenofovir was developed and validated with 100 microL human plasma. Following solid-phase extraction, the analytes were separated using a gradient mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M + H]+ ions, m/z 316 to 168 for efavirenz, m/z 248-130 for emtricitabine and m/z 288-176 for tenofovir, m/z 482-258 for rosuvastatin (IS), m/z 260-116 for propranolol (IS). The method exhibited a 100-fold linear dynamic range for all the three analytes in human plasma (20-2000, 2-200 and 20-2000 ng/mL for efavirenz, emtricitabine and tenofovir respectively). The lower limit of quantification was 2 ng/mL for emtricitabine and 20 ng/mL for both efavirenz and tenofovir with a relative standard deviation of less than 11%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The total chromatographic run time of 4 min for each sample made it possible to analyze more than 250 human plasma samples per day. The method is precise and sensitive enough for its intended purpose. The method is also successfully applied to quantify efavirenz, emtricitabine and tenofovir concentrations in a rodent pharmacokinetic study.
Asunto(s)
Adenina/análogos & derivados , Benzoxazinas/sangre , Cromatografía Líquida de Alta Presión/métodos , Desoxicitidina/análogos & derivados , Organofosfonatos/sangre , Inhibidores de la Transcriptasa Inversa/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Adenina/sangre , Adenina/química , Alquinos , Animales , Benzoxazinas/química , Ciclopropanos , Desoxicitidina/sangre , Desoxicitidina/química , Emtricitabina , Humanos , Organofosfonatos/química , Ratas , Inhibidores de la Transcriptasa Inversa/química , Extracción en Fase Sólida/métodos , TenofovirRESUMEN
The present paper describes the development of a reversed phase liquid chromatographic (RPLC) analytical method for duloxetine HCl in the presence of its impurities and degradation products generated from forced decomposition studies. The drug substance was subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. The degradation of duloxetine HCl was observed under acid hydrolysis. The drug was found to be stable in other stress conditions studied. Successful separation of the drug from the synthetic impurities and degradation products formed under stress conditions was achieved on a Zorabax XDB C18, 50 mm x 4.6 mm, 5.0 micron column using a mixture of aqueous 0.1% trifluroacetic acid, methanol, tetrahydrofuran (60:20:20, v/v/v) as mobile phase. The HPLC method developed was validated with respect to linearity, accuracy, precisions, specificity and ruggedness. To our knowledge, a rapid stability indicating LC method for duloxetine HCl has not been published elsewhere.
Asunto(s)
Nootrópicos/análisis , Tiofenos/análisis , Calibración , Cromatografía Líquida de Alta Presión , Clorhidrato de Duloxetina , Calor , Hidrólisis , Indicadores y Reactivos , Oxidación-Reducción , Fotólisis , Estándares de Referencia , Reproducibilidad de los Resultados , SolucionesRESUMEN
A two step synthesis of 2-alkynyl-4-arylquinolines has been accomplished via Pd/C-mediated regioselective C-2 alkynylation of 2,4-dichloroquinoline in water followed by Suzuki coupling at C-4 of the resulting 4-chloro derivative.
RESUMEN
We describe the utility of a Pd/C-Cu mediated method in the synthesis of 2,5-disubstituted indoles in water via a coupling-cyclization strategy. Further application of this methodology has been demonstrated in the preparation of a target indole derivative via a 7-step process the key step being the Pd/C-mediated coupling reaction.
RESUMEN
A sensitive and selective high-performance liquid chromatography-positive ion electrospray tandem mass spectrometry method was developed and validated for the quantification of amisulpride in 100 microL of human plasma. Following liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective (M + H)(+) ions, m/z 370-242 for amisulpride and m/z 341-112 for the internal standard. The assay exhibited a linear dynamic range with a lower range of 0.1-100 ng/mL and a higher range of 1-500 ng/mL of amisulpride in human plasma. The lower limit of quantification was 0.1 ng/mL with a relative standard deviation of less than 10%. Acceptable precision and accuracy were obtained for both linearity ranges. A run time of 2.0 min for each sample made it possible to analyze more than 275 human plasma samples per day. The validated method has been successfully used to analyze plasma samples for application in pharmacokinetic studies.
Asunto(s)
Cromatografía Liquida/métodos , Sulpirida/análogos & derivados , Espectrometría de Masas en Tándem/métodos , Amisulprida , Antagonistas de Dopamina/sangre , Antagonistas de Dopamina/química , Humanos , Estructura Molecular , Reproducibilidad de los Resultados , Espectrometría de Masa por Ionización de Electrospray/métodos , Sulpirida/sangre , Sulpirida/químicaRESUMEN
Phenylpropanoid glycosides are known as bioactive natural products. Two of them, grayanoside A (1) and syringalide B (2), were synthesized through a common intermediate, using benzyl as temporary protecting group following a shorter route.
Asunto(s)
Ácidos Cafeicos/síntesis química , Glucósidos/síntesis química , Glicósidos/química , Ácidos Cafeicos/química , Conformación de Carbohidratos , Secuencia de Carbohidratos , Química/métodos , Glucosa/química , Glucósidos/química , Espectroscopía de Resonancia Magnética , Modelos Químicos , Datos de Secuencia Molecular , Corteza de la Planta/metabolismo , Plantas Medicinales , Piranos/química , Especies Reactivas de OxígenoRESUMEN
Six impurities in pantoprazole sodium bulk drug substance were detected by a simple high performance liquid chromatographic method (HPLC) whose area percentage ranged from approximately 0.05 to 0.34%. Liquid chromatography-mass spectrometry (LC-MS) was performed to identify the molecular weight of the impurities. A thorough study was undertaken to characterize these impurities. These impurities were synthesized, subsequently characterized and were co-injected with the sample containing impurities and found the retention time match of the spiked impurities. Based on their spectral data (IR, NMR and MS), these impurities were characterized as; 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole (Impurity-I); 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole (Impurity-II); 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-1-oxide-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole (Impurity-III); 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1-((3,4-dimethoxy-2-pyridinyl)methyl)-1H-benzimidazole (Impurity-IV); 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1-((3,4-dimethoxy-2-pyridinyl)methyl)-1H-benzimidazole (Impurity-V); 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-1-oxide-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Impurity-VI). The formation of these impurities was proposed. The structure of the Impurity-II was unambiguously confirmed by single crystal X-ray diffraction (XRD) studies.